Adverse Drug Events Associated with sitagliptin Versus canagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Comparison Through a Meta-Analysis

INTRODUCTION: In this meta-analysis, we aimed to systematically compare the adverse drug events associated with sitagliptin (100 mg) versus canagliflozin 100 or 300 mg in patients who were treated for type 2 diabetes mellitus (T2DM). METHODS: Online databases were searched for relevant studies compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bundhun, Pravesh Kumar, Huang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167288/
https://www.ncbi.nlm.nih.gov/pubmed/30094783
http://dx.doi.org/10.1007/s13300-018-0481-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167288/
https://www.ncbi.nlm.nih.gov/pubmed/30094783
http://dx.doi.org/10.1007/s13300-018-0481-6

Ejemplares similares